GI CONNECT has summarised the highlights of the American Society of Clinical Oncology 2016 (ASCO) in Chicago and the ESMO World Congress on Gastrointestinal Cancer 2016 (WCGIC) for you.
Cancers of the upper GI tract by Dr. Andrea Sartore Bianchi
GI CONNECT has summarised the highlights of the American Society of Clinical Oncology 2016 (ASCO) in Chicago and the ESMO World Congress on Gastrointestinal Cancer 2016 (WCGIC) for you.
Cancers of the upper GI tract by Dr. Andrea Sartore Bianchi
Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.
His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Unmet needs, therapy management, and real-world experience
Make decisions for a young patient during his cancer journey
Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO
Rechallenge vs switching